Industry news
Genable Technologies is acquired by Spark Therapeutics and with it RhoNova
Genable, an Irish bio-pharmaceutical company developing novel gene therapies for the treatment of dominant genetic diseases has announced that it has completed a transaction which will see it become fully owned by Spark Therapeutics. Spark Therapeutics, a global leader in AAV-based gene therapy, has collaborated with Genable since 2014 in the development of RhoNova. RhoNova is a treatment developed by Genable to target rhodopsin-linked autosomal dominant retinitis pigmentosa (RHO-adRP), an inherited retinal disease (IRD) that leads to blindness in many cases.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins